topic

738 A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors
Daniel J Olson, Ecaterina Dumbrava, Sam Saibil, Martin Gutierez, Syma Iqbal, Davendra Sohal, Maria Apostolopoulou, Kara Moss, Deyaa Adib, Benjamin Schlechter

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A831; DOI: 10.1136/jitc-2023-SITC2023.0738
739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial
Santeri A Pakola, Victor Cervera-Carrascon, Katriina Peltola, Tuomo Alanko, Riitta Korpisaari, Marjut Jaakkola, Jorma Sormunen, Juha Kononen, James Clubb, Elise Jirovec, Tatiana Kudling, Lyna Haybout, Dafne CA Quixabeira, Claudia Kistler, Joao Santos, Suvi Sorsa, Riikka Havunen, Akseli Hemminki

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A832; DOI: 10.1136/jitc-2023-SITC2023.0739
740 Pattern of natural killer (NK) cell (CD16⁺CD56⁺) expansion correlates with response outcomes with nemvaleukin alfa treatment
Sonali Panchabhai, Marc S Ernstoff, Omid Hamid, John L Hays, David F McDermott, Vamsidhar Velcheti, Yangchun Du, Sarah Donatelli, Daniel G Smith, Ulka N Vaishampayan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A833-A834; DOI: 10.1136/jitc-2023-SITC2023.0740
741 TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies
Kyriakos P Papadopoulos, Scott A Laurie, Alexander Spira, Siqing Fu, Erika Hamilton, Brigette Ma, Judy S Wang, Manish Sharma, Quincy Chu, Anna Spreafico, Mark R Bray, Dih-Yih Chen, Emily Roberts-Thomson, Roger Sidhu, Omid Hamid

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A835; DOI: 10.1136/jitc-2023-SITC2023.0741
742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors
Jong Chul Park, David Berz, Manish Sharma, Erminia Massarelli, Ralph J Hauke, Frank Yung-Chin Tsai, David Hong, Neal Akhave, Justin A Call, Jennifer Carlisle, Rachel E Sanborn, Naomi B Haas, John Hamm, D Ross Camidge, Alexander I Spira, Vasily Andrianov, Brianne O’Neill, Heather Kinkead, Anthony W Tolcher

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A836-A837; DOI: 10.1136/jitc-2023-SITC2023.0742
743 INCLINE-101: preliminary safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TAC-001 (TLR9 agonist conjugated to a CD22 mAb) in patients with advanced or metastatic solid tumors
Cesar Perez, Jason Henry, Sunnie Kim, Anthony El-Khoueiry, Martin Gutierrez, Anna Pavlick, Joshua Lee, Sangeetha Bollini, Feng Jin, Ons Harrabi, Kevin N Heller, Timothy Humphries

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A838; DOI: 10.1136/jitc-2023-SITC2023.0743
744 Assessment of safety and immunologic activity of nemvaleukin alfa in patients with advanced solid tumors treated with less frequent intravenous dosing (ARTISTRY-3)
Sarina A Piha-Paul, Justin A Call, Alexander I Spira, Aránzazu Manzano, Emiliano Calvo, Maria J de Miguel, Shwetha Asha, Yangchun Du, Clifford DiLea, Bhaskar Rege, Rita Dalal, Sonali Panchabhai, Nehal J Lakhani

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A839-A840; DOI: 10.1136/jitc-2023-SITC2023.0744
745 Immune cell profiling of advanced-stage solid tumors patients treated with an oncolytic adenovirus encoding for TNF-a and IL-2 (TILT-123)
Dafne CA Quixabeira, Santeri A Pakola, James Clubb, Lyna Haybout, Elise Jirovec, Tatiana Kudling, Joao Santos, Victor Cervera-Carrascon, Katriina Peltola, Tuomo Alanko, Jorma Sormunen, Riitta Korpisaari, Marjut Jaakkola, Juha Kononen, Susanna Juteau, Claudia Kistler, Suvi Sorsa, Riikka Havunen, Akseli Hemminki

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A841; DOI: 10.1136/jitc-2023-SITC2023.0745
746 Cancer cachexia associated Fc receptor expression on leukocytes as potential mechanism of checkpoint inhibitor resistance in patients and in murine cancer models
Bryan Remaily, Hannah Lathrop, Justin Thomas, Kyeongmin Kim, Trang Vu, Camille Stanton, Millenium Manna, Lauren Granchie, Zhiliang Xie, Yizhen Guo, Dwight Owen, Samuel Kulp, Latha Ganesan, Chris C Coss, Mitch Phelps, Thomas Mace

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A842; DOI: 10.1136/jitc-2023-SITC2023.0746
747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors
Yazan Samhouri, Joal D Beane, Sarah Weiss, J Randolph Hecht, John Hyngstrom, Brent A Hanks, Bishwa J Ganguly, Lucy Gong, Hajime Hiraragi, Yeonhee Kim, Navid Nikoo, Heidi Gillenwater

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A843; DOI: 10.1136/jitc-2023-SITC2023.0747

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages